Low-Dose Aspirin in Heart Failure Not Complicated by Atrial Fibrillation: A Nationwide Propensity-Matched Study

JACC: Heart Failure

Volumn 6, Issue 2, 2018, Pages 156-167

  Madelaire, Christian ^a   Gislason, Gunnar ^a,b,c   Kristensen, Søren L ^d   Fosbøl, Emil L ^e   Bjerre, Jenny ^a   D'Souza, Maria ^a   Gustafsson, Finn ^e   Kober, Lars ^e   Torp Pedersen, Christian ^f,g   Schou, Morten ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c The Danish National Foundation Research Center for Heart Arrhythmia   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e Rigshospitalet   (Denmark)

^f AALBORG UNIVERSITY   (Denmark)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

antithrombotic therapy; aspirin; heart failure; sinus rhythm

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; THIAZIDE DIURETIC AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ALL CAUSE MORTALITY; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ONSET AGE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SINUS RHYTHM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; VERY ELDERLY; CAUSE OF DEATH; CLINICAL TRIAL; COMPLICATION; DENMARK; DOSE RESPONSE; INCIDENCE; MULTICENTER STUDY; PROPENSITY SCORE; REGISTER; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ASPIRIN; ATRIAL FIBRILLATION; CAUSE OF DEATH; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INCIDENCE; MALE; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85044459791     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2017.09.021     Document Type: Article

References (24)

1. Palka, I., Nessler, J., Nessler, B., Piwowarska, W., Tracz, W., Undas, A., Altered fibrin clot properties in patients with chronic heart failure and sinus rhythm: a novel prothrombotic mechanism. Heart 96 (2010), 1114–1118.
2. Gurbel, P.A., Tantry, U.S., Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. J Am Coll Cardiol HF 2 (2014), 1–14.
3. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2 (1988), 349–360.
4. Cleland, J.G., Is aspirin “the weakest link” in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis 44 (2002), 275–292.
5. Cleland, J.G., Is aspirin useful in primary prevention?. Eur Heart J 34 (2013), 3412–3418.
6. Cleland, J.G., Findlay, I., Jafri, S., et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 148 (2004), 157–164.
7. Massie, B.M., Collins, J.F., Ammon, S.E., et al., WATCH trial investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 119 (2009), 1616–1624.
8. Homma, S., Thompson, J.L.P., Pullicino, P.M., et al., WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 366 (2012), 1859–1869.
9. Cokkinos, D.V., Haralabopoulos, G.C., Kostis, J.B., Toutouzas, P.K., HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 8 (2006), 428–432.
10. Bermingham, M., Shanahan, M.K., O'Connell, E., et al. Aspirin use in heart failure: is low-dose therapy associated with mortality and morbidity benefits in a large community population?. Circ Heart Fail 7 (2014), 243–250.
11. Derry, S., Loke, Y.K., Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321 (2000), 1183–1187.
12. Segal, R., Lubart, E., Leibovitz, A., et al. Early and late effects of low-dose aspirin on renal function in elderly patients. Am J Med 115 (2003), 462–466.
13. Zannad, F., Greenberg, B., Cleland, J.G., et al. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. Eur J Heart Fail 17 (2015), 735–742.
14. Schmidt, M., Schmidt, S.A., Sandegaard, J.L., Ehrenstein, V., Pedersen, L., Sørensen, H.T., The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7 (2015), 449–490.
15. Kildemoes, H.W., Sørensen, H.T., Hallas, J., The Danish National Prescription Registry. Scand J Public Health 39:7 Suppl (2011), 38–41.
16. Schmidt, M., Pedersen, L., Sørensen, H.T., The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29 (2014), 541–549.
17. Schmidt, M., Hallas, J., Friis, S., Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999–2012. Clin Epidemiol 6 (2014), 155–168.
18. Eshaghian, S., Horwich, T.B., Fonarow, G.C., Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97 (2006), 1759–1764.
19. Dagenais, G.R., Pogue, J., Fox, K., Simoons, M.L., Yusuf, S., Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368 (2006), 581–588.
20. Kümler, T., Gislason, G.H., Kirk, V., et al. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail 10 (2008), 658–660.
21. Krarup, L.H., Boysen, G., Janjua, H., Prescott, E., Truelsen, T., Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 28 (2007), 150–154.
22. Madsen, M., Davidsen, M., Rasmussen, S., Abildstrom, S.Z., Osler, M., The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 56 (2003), 124–130.
23. Gustafsson, F., Torp-Pedersen, C., Brendorp, B., Seibaek, M., Burchardt, H., Køber, L., DIAMOND Study Group. Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur Heart J 24 (2003), 863–870.
24. Rix, T.A., Riahi, S., Overvad, K., Lundbye-Christensen, S., Schmidt, E.B., Joensen, A.M., Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. Scand Cardiovasc J 46 (2012), 149–153.